FDA Approves Nivolumab for Resected Stage IIB/C Melanoma FDA Approves Nivolumab for Resected Stage IIB/C Melanoma

The new approval expands the melanoma indication for nivolumab to earlier-stage disease.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news